23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
16:25 , Apr 19, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 12 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Full-year EPS for fiscal year ended March...
18:52 , Apr 17, 2019 |  BC Extra  |  Politics & Policy

Cummings defends drug price information request

House Energy & Commerce Committee Chairman Elijah Cummings (D-Md.) Wednesday denounced Jim Jordan (R-Ohio) for attempting to thwart the committee’s investigation into prescription drug prices. Cummings was responding to a letter Jordan sent on April...
23:16 , Apr 16, 2019 |  BC Extra  |  Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
20:54 , Apr 15, 2019 |  BC Extra  |  Clinical News

Invokana reduces composite endpoint by 30% in Type II diabetics with CKD

After years of failures in the CKD space, two agents have now shown efficacy in the indication. The latest is Invokana canagliflozin from Janssen, which said Sunday that Invokana is the only drug in nearly...
19:24 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

MedImmune's bispecific mAb for Pseudomonas-related ocular keratitis

DISEASE CATEGORY: Infectious disease INDICATION: Pseudomonas Mouse studies suggest MEDI3902, a bispecific mAb against P. aeruginosa Psl and PcrV, could help treat ocular keratitis caused by P. aeruginosa infection. In a mouse model of bacterial...
00:27 , Apr 13, 2019 |  BioCentury  |  Tools & Techniques

ctDNA inches toward new applications

After establishing itself as a key tool for tumor profiling and patient stratification, circulating tumor DNA is now beginning to make the move into monitoring response to therapy, where it promises an early read of...
17:03 , Apr 8, 2019 |  BC Extra  |  Politics & Policy

Reps. Jordan, Meadows accuse Cummings of 'partisan' drug pricing investigation

Two House Republicans have accused Rep. Elijah Cummings (D-Md.) of leading a partisan investigation into drug pricing, and implied he could leak biopharmas' sensitive, proprietary information. In letters sent to 12 biopharmas, Reps. Jim Jordan...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
20:25 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Clovis' PARP inhibitor leads to PFS of 9.1 months in pancreatic cancer

Clovis reported at AACR that first-line maintenance treatment with Rubraca rucaparib led to a median progression-free survival of 9.1 months from the start of Rubraca therapy among 19 evaluable pancreatic cancer patients in an interim...